Notícias

DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.

Aug 26 (Reuters) - Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.

West Pharmaceutical Services has delivered a strong 43.0% return over the past year, yet current checks suggest the stock is not a clear bargain. The Discounted Cash Flow (DCF) intrinsic value estimate sits close to the market price, while market multiples lean expensive. The 43.0% one year return highlights how strongly West Pharmaceutical Services has rewarded shareholders over this period and raises the bar for future expectations. Expectations for steady demand in its drug delivery and...

Forget the humanoid robots for a minute; the most potent catalyst for the stock may already be hitting the streets, and it's growing exponentially.

MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.

BLCO advances two eye-health candidates after positive trial results, with combined estimated peak sales exceeding $2 billion.

CAH enters fiscal 2027 with strong specialty growth, but IRA pricing changes, GMPD challenges and heavy CapEx pose risks.

DOCS' AI expansion is opening new growth avenues, but rising AI costs and tight pharma budgets could temper near-term gains.

AMN Healthcare's 2026 surge is backed by rebounding nurse and allied demand, stronger execution and persistent healthcare workforce shortages.

GE HealthCare's record backlog, strong Pharmaceutical Diagnostics growth and AI innovation support its growth outlook despite margin pressures.

OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.

INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.

JNJ's MONARCH QUEST 3 wins FDA 510(k) clearance, adding AI-powered planning, navigation and imaging upgrades for robotic bronchoscopy.

Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.

BTSG's nearly 59% YTD surge is backed by 23% revenue growth, rising margins and expansion in specialty pharmacy and home-based care.

SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.

Recent share performance and business backdrop West Pharmaceutical Services (WST) has drawn investor attention after a period where the stock returned 0.1% over the past month and 11.6% over the past 3 months, against a backdrop of steady reported operations. The company reports annual revenue of US$3.3b and net income of US$564.9m, supported by two primary segments. Proprietary Products contribute US$2.7b and West Vantage, which sits within that portfolio, adds US$600.6m. See our latest...

BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.

Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.

MMED's MiniMed Flex is now shipping in the U.S. with Abbott's 15-day Instinct sensor, pairing discreet app control with automated insulin delivery.

Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.

Hinge Health's nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.

ISRG is expanding in Asia Pacific with a new Penang plant to boost capacity and support rising demand for robotic-assisted surgery.

Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.

SNN launches the FLOW FLEXTEND COBLATION Wand, offering adjustable-angle access and precise tissue removal in complex joint procedures.

CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.

NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.

West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.

West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.